<DOC>
	<DOCNO>NCT00463788</DOCNO>
	<brief_summary>The primary objective study determine whether overall response cetuximab combine cisplatin good overall response cisplatin alone together show overall response cetuximab cisplatin pre-specified threshold 0.2 treatment `` triple negative '' metastatic breast cancer . The secondary objective study compare difference two treatment group use follow criterion : Progression-Free Survival ( PFS ) Time , Overall Survival ( OS ) , Time Response ( TTR ) Safety .</brief_summary>
	<brief_title>Cetuximab Cisplatin Treatment `` Triple Negative '' ( Estrogen Receptor ER Negative , Progesterone Receptor PgR Negative , Human Epidermal Growth Factor Receptor 2 HER2 Negative ) Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm diagnosis metastatic breast cancer ( Stage IV ) Estrogen Receptor [ ER ] negative , PgR negative HER2 le 3+ expression immunohistochemistry ( IHC ) No 1 prior chemotherapy receive treat metastatic breast cancer No 1 prior anthracycline and/or taxane regimen ( either adjuvant metastatic setting ) Other protocoldefined inclusion criterion may apply Prior platinum agent Prior mitomycin Known history brain metastases Other protocoldefined exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>breast</keyword>
	<keyword>metastatic</keyword>
	<keyword>triple negative</keyword>
</DOC>